Trials / Active Not Recruiting
Active Not RecruitingNCT06920901
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APG777 in Adults With Mild-to-Moderate Asthma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Apogee Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APG777 | APG777 subcutaneous injection |
| DRUG | Placebo | Matching placebo subcutaneous injection |
Timeline
- Start date
- 2025-03-27
- Primary completion
- 2026-09-01
- Completion
- 2027-03-01
- First posted
- 2025-04-10
- Last updated
- 2026-02-17
Locations
11 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06920901. Inclusion in this directory is not an endorsement.